Loading patent…
AssigneeChemagis Ltd.
InventorsItai Adin, Carmen Iustain, Guy Davidi, Alex Weisman, Moshe Bentolila, Elazar Meyer, Joseph Kaspi
Estimating the term…
Provided is a process for preparing crystalline imatinib mesylate in substantially pure α-form, which preferably includes crystallizing imatinib mesylate from an organic solvent containing imatinib and methanesulfonic acid, and seed crystals of imatinib mesylate α-form, wherein the seed crystals are added before imatinib mesylate begins to precipitate from the mixture. Also provided are stable, free-flowing imatinib mesylate crystals in substantially pure α-form, and a pharmaceutical composition containing the stable, free-flowing imatinib mesylate crystals.
A process for preparing crystalline imatinib mesylate in substantially pure α-form, the process comprising crystallizing imatinib mesylate from a solution comprising an organic solvent, imatinib and methanesulfonic acid dissolved therein, and seed crystals of substantially pure imatinib mesylate α-form, wherein the seed crystals are added before imatinib mesylate begins to precipitate from the solution.
Stable, free-flowing imatinib mesylate crystals in substantially pure α-form.
Dependencies are inferred from the claim text.